Combination therapy with FAP-targeted lymphotoxin beta receptor agonists
The combination of tumor-targeted anti-CD3 bispecific antibodies and FAP-targeted LTBR agonist antibodies addresses resistance in cancer treatments by enhancing immune infiltration and inflammation, resulting in improved tumor control and survival.
Patent Information
- Application Number
- JP2025574251
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-21
- Filing Date
- 2024-06-19
- Publication Date
- 2026-07-13
AI Technical Summary
Existing cancer treatments, such as checkpoint inhibitors and bispecific T cell engagers, face challenges with resistance mechanisms and low immunogenicity in solid tumors, limiting their effectiveness, particularly in colorectal and pancreatic cancer, necessitating therapies that enhance immune infiltration and overcome resistance.
A combination therapy using tumor-targeted anti-CD3 bispecific antibodies and FAP-targeted LTBR agonist antibodies, which synergistically activate immune infiltration by upregulating adhesion molecules and inducing high endothelial venules, administered systemically to target the tumor site.
The combination therapy significantly enhances tumor microenvironment inflammation, reduces immunosuppression, and increases immune cell infiltration, leading to more effective tumor control and improved survival compared to monotherapies.
Smart Images
Figure 2026523175000001_ABST